Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EXOSC7_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EXOSC7_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EXOSC7_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EXOSC7_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EXOSC7_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0000956110 | Skin | cSCC | nuclear-transcribed mRNA catabolic process | 59/4864 | 112/18723 | 1.46e-09 | 5.60e-08 | 59 |
GO:0061013110 | Skin | cSCC | regulation of mRNA catabolic process | 79/4864 | 166/18723 | 1.57e-09 | 5.92e-08 | 79 |
GO:1901361110 | Skin | cSCC | organic cyclic compound catabolic process | 188/4864 | 495/18723 | 1.92e-09 | 7.01e-08 | 188 |
GO:0043487110 | Skin | cSCC | regulation of RNA stability | 80/4864 | 170/18723 | 2.39e-09 | 8.52e-08 | 80 |
GO:004348824 | Skin | cSCC | regulation of mRNA stability | 75/4864 | 158/18723 | 4.64e-09 | 1.55e-07 | 75 |
GO:00004604 | Skin | cSCC | maturation of 5.8S rRNA | 25/4864 | 35/18723 | 2.34e-08 | 6.68e-07 | 25 |
GO:00311234 | Skin | cSCC | RNA 3'-end processing | 58/4864 | 116/18723 | 2.47e-08 | 6.89e-07 | 58 |
GO:00905014 | Skin | cSCC | RNA phosphodiester bond hydrolysis | 71/4864 | 152/18723 | 2.72e-08 | 7.41e-07 | 71 |
GO:006115718 | Skin | cSCC | mRNA destabilization | 44/4864 | 84/18723 | 2.14e-07 | 4.60e-06 | 44 |
GO:006101418 | Skin | cSCC | positive regulation of mRNA catabolic process | 45/4864 | 87/18723 | 2.53e-07 | 5.29e-06 | 45 |
GO:005077918 | Skin | cSCC | RNA destabilization | 44/4864 | 88/18723 | 1.16e-06 | 2.03e-05 | 44 |
GO:00004694 | Skin | cSCC | cleavage involved in rRNA processing | 19/4864 | 27/18723 | 1.72e-06 | 2.88e-05 | 19 |
GO:003424915 | Skin | cSCC | negative regulation of cellular amide metabolic process | 104/4864 | 273/18723 | 6.44e-06 | 9.00e-05 | 104 |
GO:001714814 | Skin | cSCC | negative regulation of translation | 93/4864 | 245/18723 | 2.28e-05 | 2.63e-04 | 93 |
GO:000028818 | Skin | cSCC | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 29/4864 | 56/18723 | 3.25e-05 | 3.56e-04 | 29 |
GO:00004664 | Skin | cSCC | maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 16/4864 | 24/18723 | 3.35e-05 | 3.66e-04 | 16 |
GO:00903054 | Skin | cSCC | nucleic acid phosphodiester bond hydrolysis | 97/4864 | 261/18723 | 4.08e-05 | 4.34e-04 | 97 |
GO:00905034 | Skin | cSCC | RNA phosphodiester bond hydrolysis, exonucleolytic | 23/4864 | 42/18723 | 6.79e-05 | 6.58e-04 | 23 |
GO:00002914 | Skin | cSCC | nuclear-transcribed mRNA catabolic process, exonucleolytic | 13/4864 | 19/18723 | 1.27e-04 | 1.16e-03 | 13 |
GO:00439284 | Skin | cSCC | exonucleolytic catabolism of deadenylated mRNA | 10/4864 | 13/18723 | 1.78e-04 | 1.50e-03 | 10 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EXOSC7 | SNV | Missense_Mutation | rs774989692 | c.58N>A | p.Glu20Lys | p.E20K | Q15024 | protein_coding | tolerated(0.13) | benign(0.001) | TCGA-D8-A1JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
EXOSC7 | insertion | Nonsense_Mutation | novel | c.405_406insACACACTGACAAATCCAGGTCACAGTGCTGGTCTGGTTCATTACA | p.Leu135_Tyr136insThrHisTerGlnIleGlnValThrValLeuValTrpPheIleThr | p.L135_Y136insTH*QIQVTVLVWFIT | Q15024 | protein_coding | | | TCGA-AO-A0JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophospamide | SD |
EXOSC7 | SNV | Missense_Mutation | rs140459270 | c.407N>G | p.Tyr136Cys | p.Y136C | Q15024 | protein_coding | deleterious(0.01) | possibly_damaging(0.558) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EXOSC7 | SNV | Missense_Mutation | rs774516290 | c.442N>G | p.Leu148Val | p.L148V | Q15024 | protein_coding | deleterious(0.01) | benign(0.12) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EXOSC7 | SNV | Missense_Mutation | | c.371N>G | p.Leu124Arg | p.L124R | Q15024 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
EXOSC7 | SNV | Missense_Mutation | rs770116250 | c.530C>T | p.Ser177Leu | p.S177L | Q15024 | protein_coding | tolerated(0.26) | benign(0.011) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EXOSC7 | SNV | Missense_Mutation | novel | c.670N>A | p.Ala224Thr | p.A224T | Q15024 | protein_coding | deleterious(0.01) | possibly_damaging(0.463) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
EXOSC7 | SNV | Missense_Mutation | | c.581N>C | p.Val194Ala | p.V194A | Q15024 | protein_coding | tolerated(0.06) | benign(0.025) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EXOSC7 | SNV | Missense_Mutation | | c.243N>A | p.Phe81Leu | p.F81L | Q15024 | protein_coding | deleterious(0.01) | possibly_damaging(0.56) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
EXOSC7 | SNV | Missense_Mutation | | c.98N>T | p.Arg33Leu | p.R33L | Q15024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |